Cancer research saves lives and leads to improved outcomes for patients. But federal cancer research funding may be in jeopardy for 2026.

Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) is one of the best penny stocks under $1 to buy now. Earlier in June, Mersana ...

Erica Campbell chose a mastectomy. That choice gave her power — and helped her make peace with her biggest regret.

ImmunityBio sees bullish momentum from ASCO data and UK approval for ANKTIVA, despite FDA and cash risks. Check out why IBRX ...

Today's top stories from ASCO 2024 include AstraZeneca taking a solid tumor CAR-T for liver cancer to a Phase 2 clinical trial.

A different study presented at the 2025 ASCO Annual Meeting showed that one specific diet may benefit people with colon ...

ASCO, for its part, tried (futilely) to help attendees navigate the murky waters. Upon registration, attendees could choose to don a red pin (keep a 6-foot distance), ...

ASCO showcased the payoff for new cancer medicines: longer lives. By Matthew Herper, Angus Chen, Adam Feuerstein, and Katherine MacPhail June 7, 2023. Reprints.

ASCO: With hopes high, Regeneron misses mark with just one complete response in solid tumor trial so far. By Gabrielle Masson May 23, 2024 5:00pm. Regeneron Pharmaceuticals ASCO 2024 Clinical ...

ASCO will continue to support oncologists in providing timely, evidence-based, full scope care to all patients, as their ethical duties require. Acknowledgment The authors thank all members of the ...